Review



mouse pf4 elisa kit  (Elabscience Biotechnology)


Bioz Verified Symbol Elabscience Biotechnology is a verified supplier
Bioz Manufacturer Symbol Elabscience Biotechnology manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Elabscience Biotechnology mouse pf4 elisa kit
    TLR8 agonist activates <t>PF4-CXCR3</t> pathway to shape the TIME. A t-SNE plot showing the distribution of all cells from the control and agonist-treated groups combined ( n = 15,745 cells). B t-SNE plot depicting the distribution of distinct immune cell types. C Dot plot displaying the marker genes used to define each immune cell population. D Density plot showing the distribution of Tlr8-expressing cells across the t-SNE map. E Violin plot illustrating Tlr8 expression levels across different immune cell types. F Circle plot depicting the strength of Pf4–Cxcr3 receptor–ligand interactions between distinct cell types in the control and motolimod-treated groups. G Differential gene expression profiles of neutrophils, macrophages, cDC2, and CD8 + T cells. H Bubble plot comparing changes in specific receptor–ligand interactions between the control and motolimod-treated groups, focusing on macrophage-to-cCD4 + T signaling, cDC2-to-cCD4 + T signaling, and CD8 + T-to-cCD4 + T signaling. I Violin plot showing differential expression of Cxcr3 in cCD4 + T and Tregs, analyzed using the Wilcoxon rank-sum test. ns, not significant; ** P < 0.01
    Mouse Pf4 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Mouse+PF4+(Platelet+Factor+4)+ELISA+Kit/pmc12901762-237-8-12
    Average 94 stars, based on 6 article reviews
    mouse pf4 elisa kit - by Bioz Stars, 2026-11
    94/100 stars

    Images

    1) Product Images from "TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms"

    Article Title: TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms

    Journal: Cancer Immunology, Immunotherapy : CII

    doi: 10.1007/s00262-026-04329-8

    TLR8 agonist activates PF4-CXCR3 pathway to shape the TIME. A t-SNE plot showing the distribution of all cells from the control and agonist-treated groups combined ( n = 15,745 cells). B t-SNE plot depicting the distribution of distinct immune cell types. C Dot plot displaying the marker genes used to define each immune cell population. D Density plot showing the distribution of Tlr8-expressing cells across the t-SNE map. E Violin plot illustrating Tlr8 expression levels across different immune cell types. F Circle plot depicting the strength of Pf4–Cxcr3 receptor–ligand interactions between distinct cell types in the control and motolimod-treated groups. G Differential gene expression profiles of neutrophils, macrophages, cDC2, and CD8 + T cells. H Bubble plot comparing changes in specific receptor–ligand interactions between the control and motolimod-treated groups, focusing on macrophage-to-cCD4 + T signaling, cDC2-to-cCD4 + T signaling, and CD8 + T-to-cCD4 + T signaling. I Violin plot showing differential expression of Cxcr3 in cCD4 + T and Tregs, analyzed using the Wilcoxon rank-sum test. ns, not significant; ** P < 0.01
    Figure Legend Snippet: TLR8 agonist activates PF4-CXCR3 pathway to shape the TIME. A t-SNE plot showing the distribution of all cells from the control and agonist-treated groups combined ( n = 15,745 cells). B t-SNE plot depicting the distribution of distinct immune cell types. C Dot plot displaying the marker genes used to define each immune cell population. D Density plot showing the distribution of Tlr8-expressing cells across the t-SNE map. E Violin plot illustrating Tlr8 expression levels across different immune cell types. F Circle plot depicting the strength of Pf4–Cxcr3 receptor–ligand interactions between distinct cell types in the control and motolimod-treated groups. G Differential gene expression profiles of neutrophils, macrophages, cDC2, and CD8 + T cells. H Bubble plot comparing changes in specific receptor–ligand interactions between the control and motolimod-treated groups, focusing on macrophage-to-cCD4 + T signaling, cDC2-to-cCD4 + T signaling, and CD8 + T-to-cCD4 + T signaling. I Violin plot showing differential expression of Cxcr3 in cCD4 + T and Tregs, analyzed using the Wilcoxon rank-sum test. ns, not significant; ** P < 0.01

    Techniques Used: Control, Marker, Expressing, Gene Expression, Quantitative Proteomics

    TLR8 agonist induces PF4 expression through NF-κB signaling pathway. A , B qRT-PCR analysis of Pf4 expression in mouse and human macrophages in the motolimod-treated and control groups ( n = 3). C , D Luminescence assay showing NF-κB pathway activation in mouse and human macrophages following motolimod stimulation ( n = 3). E , F qRT-PCR analysis of Rela expression in Rela -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). G , H Western blotting showing p65 protein levels in RELA -knockdown and control mouse and human macrophages with or without motolimod treatment. I , J qRT-PCR analysis of Pf4 / PF4 expression in Rela / RELA -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). K ELISA quantification of Pf4 levels in the culture supernatant from Rela -knockdown and control mouse macrophages with or without motolimod treatment ( n = 3). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001
    Figure Legend Snippet: TLR8 agonist induces PF4 expression through NF-κB signaling pathway. A , B qRT-PCR analysis of Pf4 expression in mouse and human macrophages in the motolimod-treated and control groups ( n = 3). C , D Luminescence assay showing NF-κB pathway activation in mouse and human macrophages following motolimod stimulation ( n = 3). E , F qRT-PCR analysis of Rela expression in Rela -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). G , H Western blotting showing p65 protein levels in RELA -knockdown and control mouse and human macrophages with or without motolimod treatment. I , J qRT-PCR analysis of Pf4 / PF4 expression in Rela / RELA -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). K ELISA quantification of Pf4 levels in the culture supernatant from Rela -knockdown and control mouse macrophages with or without motolimod treatment ( n = 3). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001

    Techniques Used: Expressing, Quantitative RT-PCR, Control, Luminescence Assay, Activation Assay, Knockdown, Western Blot, Enzyme-linked Immunosorbent Assay

    PF4 remodels the TIME and suppresses tumor growth. A , B Tumor growth curves and terminal tumor weights in C57BL/6 mice bearing AKR or MC38 tumors with or without Pf4 overexpression, treated with or without motolimod administered every three days ( n = 6). C Percentage of CD45 + cells among live cells in AKR and MC38 tumor models ( n = 6). D Percentage of cCD4 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). E Percentage of CD8 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). F Percentage of Tregs within the CD45 + population in AKR and MC38 tumor models ( n = 6). G Ratios of cCD4 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). H Ratios of CD8 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). I Representative immunofluorescence staining of CD8α (red) and DAPI (blue) in MC38-Vector or MC38-Pf4-OE tumor sections with or without motolimod treatment. Scale bar: 50 μm. J Quantification of CD8α + positive cell ratio (%) relative to total DAPI + nucleated cells per section ( n = 6). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001
    Figure Legend Snippet: PF4 remodels the TIME and suppresses tumor growth. A , B Tumor growth curves and terminal tumor weights in C57BL/6 mice bearing AKR or MC38 tumors with or without Pf4 overexpression, treated with or without motolimod administered every three days ( n = 6). C Percentage of CD45 + cells among live cells in AKR and MC38 tumor models ( n = 6). D Percentage of cCD4 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). E Percentage of CD8 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). F Percentage of Tregs within the CD45 + population in AKR and MC38 tumor models ( n = 6). G Ratios of cCD4 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). H Ratios of CD8 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). I Representative immunofluorescence staining of CD8α (red) and DAPI (blue) in MC38-Vector or MC38-Pf4-OE tumor sections with or without motolimod treatment. Scale bar: 50 μm. J Quantification of CD8α + positive cell ratio (%) relative to total DAPI + nucleated cells per section ( n = 6). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001

    Techniques Used: Over Expression, Immunofluorescence, Staining, Plasmid Preparation

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: Mediterranean Diet and Atherothrombosis Biomarkers: A Randomized Controlled Trial.
    Article Snippet: .. [1,27] Atherothrombosis Biomarkers: ELISA kits were used to quantify the levels of: fibrinogen (Human Fibrinogen SimpleStep ELISA kit, ref. ab208036, abcam, UK), PAI-1 (Human PAI1 SimpleStep ELISA kit (SERPINE1), ref. ab184863, abcam, UK), platelet factor-4 (PF4 (CXCL4) Human SimpleStep ELISA kit, ref. ab189573, abcam, UK), and prothrombin fragment 1+2 (Human F1+2 (prothrombin fragment 1+2) ELISA kit, ref. E-EL-H1793, Elabscience, USA). .. The concentrations of antithrombin (Antithrombin III, ref. SR-1102016, Spinreact, Spain) and d-dimer (D-Dimer, ref. SR1709231, Spinreact, Spain) were assessed by immunoturbidimetry, and of NEFAs (Non-Esterified Fatty Acids, ref. FA115, Randox, Spain) using a colorimetric technique in an ABX-Pentra 400 autoanalyzer (Horiba-ABX, France).



    Similar Products

    94
    Cusabio e07884m
    E07884m, supplied by Cusabio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Mouse+Platelet+Factor+4%2CPF-4+ELISA+Kit/pm42776840-801-24-28
    Average 94 stars, based on 1 article reviews
    e07884m - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    R&D Systems platelet factor 4
    Platelet Factor 4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Mouse+Thrombopoietin+Quantikine+ELISA+Kit/bio_rxiv__64898__2026__04__01__715884-133-38-41
    Average 94 stars, based on 1 article reviews
    platelet factor 4 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology mouse pf4 elisa kit
    TLR8 agonist activates <t>PF4-CXCR3</t> pathway to shape the TIME. A t-SNE plot showing the distribution of all cells from the control and agonist-treated groups combined ( n = 15,745 cells). B t-SNE plot depicting the distribution of distinct immune cell types. C Dot plot displaying the marker genes used to define each immune cell population. D Density plot showing the distribution of Tlr8-expressing cells across the t-SNE map. E Violin plot illustrating Tlr8 expression levels across different immune cell types. F Circle plot depicting the strength of Pf4–Cxcr3 receptor–ligand interactions between distinct cell types in the control and motolimod-treated groups. G Differential gene expression profiles of neutrophils, macrophages, cDC2, and CD8 + T cells. H Bubble plot comparing changes in specific receptor–ligand interactions between the control and motolimod-treated groups, focusing on macrophage-to-cCD4 + T signaling, cDC2-to-cCD4 + T signaling, and CD8 + T-to-cCD4 + T signaling. I Violin plot showing differential expression of Cxcr3 in cCD4 + T and Tregs, analyzed using the Wilcoxon rank-sum test. ns, not significant; ** P < 0.01
    Mouse Pf4 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Mouse+PF4+(Platelet+Factor+4)+ELISA+Kit/pmc12901762-237-8-12
    Average 94 stars, based on 1 article reviews
    mouse pf4 elisa kit - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Cedarlane anti pf4 h antibody
    (a) Effects of complement inhibitors on complement activation by KKO ICs. Healthy donor plasma was pre-incubated with complement inhibitors (BBK32, a small molecule C1 inhibitor, 25 μg/ml), C1-esterase inhibitor (C1-INH, 100 μg/ml), Cp40 (a C3 inhibitor, 20 μM), anti-C1q blocking antibody (300 μg/ml), IV.3 (10 μg/ml), an FcγRIIA blocking antibody, anti-C5 monoclonal antibody (50 μg/ml) or isotype controls before adding <t>PF4(P)/heparin(H)</t> antigen and KKO. As shown, C3 activation was inhibited by C1/C3 blocking agents, but not by anti-C5 or anti-FcγRIIA. ***p<0.0001, ns=not significant, using the One-way ANOVA with Tukey’s multiple comparisons test (B) Inhibitory concentration curve of complement inhibitors. The inhibitory concentration leading to half-maximal C3c generation (IC 50 ) was determined in the immunocapture assay, by incubating healthy donor whole blood with increasing concentrations (x-axis) of complement inhibitors as indicated in the graph. Pre-incubation of whole blood with inhibitors was followed by addition of PF4, H and KKO to form in situ ICs and complement activation measured as described in subheading 3.1.2 . Classical pathway (CP) and CP/alternative pathway (AP) inhibitors inhibited complement activation but AP pathway specific inhibitor had no effect. Graph shows the C3c generated relative to KKO ICs <t>(PF4/H/KKO).</t> Fig. 3a adapted from Blood[ 9 ] with permission from American Society of Hematology. Fig 3b adapted from Journal of Thrombosis and Haemostasis [ 11 ] with permission from the International Society on Thrombosis and Haemostasis.
    Anti Pf4 H Antibody, supplied by Cedarlane, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Anti-Human+Platelet+Factor+4+(requires+heparin+for+binding)%2C+Purified+(Clone%3A+KKO)+(Mouse+IgG2b)/pmc13712641-59-78-91
    Average 94 stars, based on 1 article reviews
    anti pf4 h antibody - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    86
    Agenus Inc anti platelet factor pf 4 antibody formation
    (a) Effects of complement inhibitors on complement activation by KKO ICs. Healthy donor plasma was pre-incubated with complement inhibitors (BBK32, a small molecule C1 inhibitor, 25 μg/ml), C1-esterase inhibitor (C1-INH, 100 μg/ml), Cp40 (a C3 inhibitor, 20 μM), anti-C1q blocking antibody (300 μg/ml), IV.3 (10 μg/ml), an FcγRIIA blocking antibody, anti-C5 monoclonal antibody (50 μg/ml) or isotype controls before adding <t>PF4(P)/heparin(H)</t> antigen and KKO. As shown, C3 activation was inhibited by C1/C3 blocking agents, but not by anti-C5 or anti-FcγRIIA. ***p<0.0001, ns=not significant, using the One-way ANOVA with Tukey’s multiple comparisons test (B) Inhibitory concentration curve of complement inhibitors. The inhibitory concentration leading to half-maximal C3c generation (IC 50 ) was determined in the immunocapture assay, by incubating healthy donor whole blood with increasing concentrations (x-axis) of complement inhibitors as indicated in the graph. Pre-incubation of whole blood with inhibitors was followed by addition of PF4, H and KKO to form in situ ICs and complement activation measured as described in subheading 3.1.2 . Classical pathway (CP) and CP/alternative pathway (AP) inhibitors inhibited complement activation but AP pathway specific inhibitor had no effect. Graph shows the C3c generated relative to KKO ICs <t>(PF4/H/KKO).</t> Fig. 3a adapted from Blood[ 9 ] with permission from American Society of Hematology. Fig 3b adapted from Journal of Thrombosis and Haemostasis [ 11 ] with permission from the International Society on Thrombosis and Haemostasis.
    Anti Platelet Factor Pf 4 Antibody Formation, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/4+antibody+assay+factor+healthtest+heparin+platelet/pmc12777639-84-11-13
    Average 86 stars, based on 1 article reviews
    anti platelet factor pf 4 antibody formation - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology pf4
    (a) Effects of complement inhibitors on complement activation by KKO ICs. Healthy donor plasma was pre-incubated with complement inhibitors (BBK32, a small molecule C1 inhibitor, 25 μg/ml), C1-esterase inhibitor (C1-INH, 100 μg/ml), Cp40 (a C3 inhibitor, 20 μM), anti-C1q blocking antibody (300 μg/ml), IV.3 (10 μg/ml), an FcγRIIA blocking antibody, anti-C5 monoclonal antibody (50 μg/ml) or isotype controls before adding <t>PF4(P)/heparin(H)</t> antigen and KKO. As shown, C3 activation was inhibited by C1/C3 blocking agents, but not by anti-C5 or anti-FcγRIIA. ***p<0.0001, ns=not significant, using the One-way ANOVA with Tukey’s multiple comparisons test (B) Inhibitory concentration curve of complement inhibitors. The inhibitory concentration leading to half-maximal C3c generation (IC 50 ) was determined in the immunocapture assay, by incubating healthy donor whole blood with increasing concentrations (x-axis) of complement inhibitors as indicated in the graph. Pre-incubation of whole blood with inhibitors was followed by addition of PF4, H and KKO to form in situ ICs and complement activation measured as described in subheading 3.1.2 . Classical pathway (CP) and CP/alternative pathway (AP) inhibitors inhibited complement activation but AP pathway specific inhibitor had no effect. Graph shows the C3c generated relative to KKO ICs <t>(PF4/H/KKO).</t> Fig. 3a adapted from Blood[ 9 ] with permission from American Society of Hematology. Fig 3b adapted from Journal of Thrombosis and Haemostasis [ 11 ] with permission from the International Society on Thrombosis and Haemostasis.
    Pf4, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Mouse+PF4+(Platelet+Factor+4)+ELISA+Kit/pm41273866-92-5-7
    Average 94 stars, based on 1 article reviews
    pf4 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    Elabscience Biotechnology human pf4 platelet factor 4 elisa kit
    (a) Effects of complement inhibitors on complement activation by KKO ICs. Healthy donor plasma was pre-incubated with complement inhibitors (BBK32, a small molecule C1 inhibitor, 25 μg/ml), C1-esterase inhibitor (C1-INH, 100 μg/ml), Cp40 (a C3 inhibitor, 20 μM), anti-C1q blocking antibody (300 μg/ml), IV.3 (10 μg/ml), an FcγRIIA blocking antibody, anti-C5 monoclonal antibody (50 μg/ml) or isotype controls before adding <t>PF4(P)/heparin(H)</t> antigen and KKO. As shown, C3 activation was inhibited by C1/C3 blocking agents, but not by anti-C5 or anti-FcγRIIA. ***p<0.0001, ns=not significant, using the One-way ANOVA with Tukey’s multiple comparisons test (B) Inhibitory concentration curve of complement inhibitors. The inhibitory concentration leading to half-maximal C3c generation (IC 50 ) was determined in the immunocapture assay, by incubating healthy donor whole blood with increasing concentrations (x-axis) of complement inhibitors as indicated in the graph. Pre-incubation of whole blood with inhibitors was followed by addition of PF4, H and KKO to form in situ ICs and complement activation measured as described in subheading 3.1.2 . Classical pathway (CP) and CP/alternative pathway (AP) inhibitors inhibited complement activation but AP pathway specific inhibitor had no effect. Graph shows the C3c generated relative to KKO ICs <t>(PF4/H/KKO).</t> Fig. 3a adapted from Blood[ 9 ] with permission from American Society of Hematology. Fig 3b adapted from Journal of Thrombosis and Haemostasis [ 11 ] with permission from the International Society on Thrombosis and Haemostasis.
    Human Pf4 Platelet Factor 4 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/platelet+factor+4/Human%3FPF4+(Platelet%3FFactor%3F4)%3FELISA%3FKit/pmc12657974-106-17-16
    Average 93 stars, based on 1 article reviews
    human pf4 platelet factor 4 elisa kit - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    TLR8 agonist activates PF4-CXCR3 pathway to shape the TIME. A t-SNE plot showing the distribution of all cells from the control and agonist-treated groups combined ( n = 15,745 cells). B t-SNE plot depicting the distribution of distinct immune cell types. C Dot plot displaying the marker genes used to define each immune cell population. D Density plot showing the distribution of Tlr8-expressing cells across the t-SNE map. E Violin plot illustrating Tlr8 expression levels across different immune cell types. F Circle plot depicting the strength of Pf4–Cxcr3 receptor–ligand interactions between distinct cell types in the control and motolimod-treated groups. G Differential gene expression profiles of neutrophils, macrophages, cDC2, and CD8 + T cells. H Bubble plot comparing changes in specific receptor–ligand interactions between the control and motolimod-treated groups, focusing on macrophage-to-cCD4 + T signaling, cDC2-to-cCD4 + T signaling, and CD8 + T-to-cCD4 + T signaling. I Violin plot showing differential expression of Cxcr3 in cCD4 + T and Tregs, analyzed using the Wilcoxon rank-sum test. ns, not significant; ** P < 0.01

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms

    doi: 10.1007/s00262-026-04329-8

    Figure Lengend Snippet: TLR8 agonist activates PF4-CXCR3 pathway to shape the TIME. A t-SNE plot showing the distribution of all cells from the control and agonist-treated groups combined ( n = 15,745 cells). B t-SNE plot depicting the distribution of distinct immune cell types. C Dot plot displaying the marker genes used to define each immune cell population. D Density plot showing the distribution of Tlr8-expressing cells across the t-SNE map. E Violin plot illustrating Tlr8 expression levels across different immune cell types. F Circle plot depicting the strength of Pf4–Cxcr3 receptor–ligand interactions between distinct cell types in the control and motolimod-treated groups. G Differential gene expression profiles of neutrophils, macrophages, cDC2, and CD8 + T cells. H Bubble plot comparing changes in specific receptor–ligand interactions between the control and motolimod-treated groups, focusing on macrophage-to-cCD4 + T signaling, cDC2-to-cCD4 + T signaling, and CD8 + T-to-cCD4 + T signaling. I Violin plot showing differential expression of Cxcr3 in cCD4 + T and Tregs, analyzed using the Wilcoxon rank-sum test. ns, not significant; ** P < 0.01

    Article Snippet: Pf4 levels in culture supernatants were quantified using Mouse PF4 ELISA Kit (Elabscience, #E-EL-M3080) according to the manufacturer’s instructions.

    Techniques: Control, Marker, Expressing, Gene Expression, Quantitative Proteomics

    TLR8 agonist induces PF4 expression through NF-κB signaling pathway. A , B qRT-PCR analysis of Pf4 expression in mouse and human macrophages in the motolimod-treated and control groups ( n = 3). C , D Luminescence assay showing NF-κB pathway activation in mouse and human macrophages following motolimod stimulation ( n = 3). E , F qRT-PCR analysis of Rela expression in Rela -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). G , H Western blotting showing p65 protein levels in RELA -knockdown and control mouse and human macrophages with or without motolimod treatment. I , J qRT-PCR analysis of Pf4 / PF4 expression in Rela / RELA -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). K ELISA quantification of Pf4 levels in the culture supernatant from Rela -knockdown and control mouse macrophages with or without motolimod treatment ( n = 3). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms

    doi: 10.1007/s00262-026-04329-8

    Figure Lengend Snippet: TLR8 agonist induces PF4 expression through NF-κB signaling pathway. A , B qRT-PCR analysis of Pf4 expression in mouse and human macrophages in the motolimod-treated and control groups ( n = 3). C , D Luminescence assay showing NF-κB pathway activation in mouse and human macrophages following motolimod stimulation ( n = 3). E , F qRT-PCR analysis of Rela expression in Rela -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). G , H Western blotting showing p65 protein levels in RELA -knockdown and control mouse and human macrophages with or without motolimod treatment. I , J qRT-PCR analysis of Pf4 / PF4 expression in Rela / RELA -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). K ELISA quantification of Pf4 levels in the culture supernatant from Rela -knockdown and control mouse macrophages with or without motolimod treatment ( n = 3). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001

    Article Snippet: Pf4 levels in culture supernatants were quantified using Mouse PF4 ELISA Kit (Elabscience, #E-EL-M3080) according to the manufacturer’s instructions.

    Techniques: Expressing, Quantitative RT-PCR, Control, Luminescence Assay, Activation Assay, Knockdown, Western Blot, Enzyme-linked Immunosorbent Assay

    PF4 remodels the TIME and suppresses tumor growth. A , B Tumor growth curves and terminal tumor weights in C57BL/6 mice bearing AKR or MC38 tumors with or without Pf4 overexpression, treated with or without motolimod administered every three days ( n = 6). C Percentage of CD45 + cells among live cells in AKR and MC38 tumor models ( n = 6). D Percentage of cCD4 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). E Percentage of CD8 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). F Percentage of Tregs within the CD45 + population in AKR and MC38 tumor models ( n = 6). G Ratios of cCD4 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). H Ratios of CD8 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). I Representative immunofluorescence staining of CD8α (red) and DAPI (blue) in MC38-Vector or MC38-Pf4-OE tumor sections with or without motolimod treatment. Scale bar: 50 μm. J Quantification of CD8α + positive cell ratio (%) relative to total DAPI + nucleated cells per section ( n = 6). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms

    doi: 10.1007/s00262-026-04329-8

    Figure Lengend Snippet: PF4 remodels the TIME and suppresses tumor growth. A , B Tumor growth curves and terminal tumor weights in C57BL/6 mice bearing AKR or MC38 tumors with or without Pf4 overexpression, treated with or without motolimod administered every three days ( n = 6). C Percentage of CD45 + cells among live cells in AKR and MC38 tumor models ( n = 6). D Percentage of cCD4 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). E Percentage of CD8 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). F Percentage of Tregs within the CD45 + population in AKR and MC38 tumor models ( n = 6). G Ratios of cCD4 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). H Ratios of CD8 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). I Representative immunofluorescence staining of CD8α (red) and DAPI (blue) in MC38-Vector or MC38-Pf4-OE tumor sections with or without motolimod treatment. Scale bar: 50 μm. J Quantification of CD8α + positive cell ratio (%) relative to total DAPI + nucleated cells per section ( n = 6). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001

    Article Snippet: Pf4 levels in culture supernatants were quantified using Mouse PF4 ELISA Kit (Elabscience, #E-EL-M3080) according to the manufacturer’s instructions.

    Techniques: Over Expression, Immunofluorescence, Staining, Plasmid Preparation

    (a) Effects of complement inhibitors on complement activation by KKO ICs. Healthy donor plasma was pre-incubated with complement inhibitors (BBK32, a small molecule C1 inhibitor, 25 μg/ml), C1-esterase inhibitor (C1-INH, 100 μg/ml), Cp40 (a C3 inhibitor, 20 μM), anti-C1q blocking antibody (300 μg/ml), IV.3 (10 μg/ml), an FcγRIIA blocking antibody, anti-C5 monoclonal antibody (50 μg/ml) or isotype controls before adding PF4(P)/heparin(H) antigen and KKO. As shown, C3 activation was inhibited by C1/C3 blocking agents, but not by anti-C5 or anti-FcγRIIA. ***p<0.0001, ns=not significant, using the One-way ANOVA with Tukey’s multiple comparisons test (B) Inhibitory concentration curve of complement inhibitors. The inhibitory concentration leading to half-maximal C3c generation (IC 50 ) was determined in the immunocapture assay, by incubating healthy donor whole blood with increasing concentrations (x-axis) of complement inhibitors as indicated in the graph. Pre-incubation of whole blood with inhibitors was followed by addition of PF4, H and KKO to form in situ ICs and complement activation measured as described in subheading 3.1.2 . Classical pathway (CP) and CP/alternative pathway (AP) inhibitors inhibited complement activation but AP pathway specific inhibitor had no effect. Graph shows the C3c generated relative to KKO ICs (PF4/H/KKO). Fig. 3a adapted from Blood[ 9 ] with permission from American Society of Hematology. Fig 3b adapted from Journal of Thrombosis and Haemostasis [ 11 ] with permission from the International Society on Thrombosis and Haemostasis.

    Journal: Methods in molecular biology (Clifton, N.J.)

    Article Title: Methods to examine complement activation by HIT immune complexes

    doi: 10.1007/978-1-0716-5376-0_10

    Figure Lengend Snippet: (a) Effects of complement inhibitors on complement activation by KKO ICs. Healthy donor plasma was pre-incubated with complement inhibitors (BBK32, a small molecule C1 inhibitor, 25 μg/ml), C1-esterase inhibitor (C1-INH, 100 μg/ml), Cp40 (a C3 inhibitor, 20 μM), anti-C1q blocking antibody (300 μg/ml), IV.3 (10 μg/ml), an FcγRIIA blocking antibody, anti-C5 monoclonal antibody (50 μg/ml) or isotype controls before adding PF4(P)/heparin(H) antigen and KKO. As shown, C3 activation was inhibited by C1/C3 blocking agents, but not by anti-C5 or anti-FcγRIIA. ***p<0.0001, ns=not significant, using the One-way ANOVA with Tukey’s multiple comparisons test (B) Inhibitory concentration curve of complement inhibitors. The inhibitory concentration leading to half-maximal C3c generation (IC 50 ) was determined in the immunocapture assay, by incubating healthy donor whole blood with increasing concentrations (x-axis) of complement inhibitors as indicated in the graph. Pre-incubation of whole blood with inhibitors was followed by addition of PF4, H and KKO to form in situ ICs and complement activation measured as described in subheading 3.1.2 . Classical pathway (CP) and CP/alternative pathway (AP) inhibitors inhibited complement activation but AP pathway specific inhibitor had no effect. Graph shows the C3c generated relative to KKO ICs (PF4/H/KKO). Fig. 3a adapted from Blood[ 9 ] with permission from American Society of Hematology. Fig 3b adapted from Journal of Thrombosis and Haemostasis [ 11 ] with permission from the International Society on Thrombosis and Haemostasis.

    Article Snippet: 2.1.1 Complement activation in plasma or whole blood Fresh or frozen healthy donor plasma prepared from healthy donor whole blood collected in acid-citrate-dextrose solution A (ACD-A) or whole blood collected in ACD-A {Baxter Healthcare Corporation, Deerfield, IL, Trisodium citrate, 22.0 g/L (85.3 mM), citric acid, 8.0 g/L (41.6 mM), and dextrose, 24.5 g/L (136 mM)} using the ratio of ACD-A to blood as 1:7 (v/v). ( see Notes 1 – 4 ) 1.5 ml micro-centrifuge tubes Capture antibody: Anti-PF4/H antibody (KKO, a monoclonal anti-PF4/heparin antibody [ 13 ]; catalog # CL2767AP, Cedarlane) Patient and control antibodies (purified IgG or frozen plasma/serum samples) Platelet factor 4 (PF4, Abcam).

    Techniques: Immunoaffinity Purification, Activation Assay, Clinical Proteomics, Incubation, Blocking Assay, Concentration Assay, In Situ, Generated